Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance

IF 2.5 4区 医学 Q2 PSYCHIATRY
Yun Yu , Xijin Wang , Ruiling Zhang , Keqing Li , Gang Wang , Jindong Chen , Meijuan Sun , Zhiyuan Xun , Xiaodong Yang , Guijun Zhao , Haiyun Li , Xuejun Liu
{"title":"Safety and effectiveness of oral blonanserin for schizophrenia in adolescents in China: Data from a 12-week post-marketing surveillance","authors":"Yun Yu ,&nbsp;Xijin Wang ,&nbsp;Ruiling Zhang ,&nbsp;Keqing Li ,&nbsp;Gang Wang ,&nbsp;Jindong Chen ,&nbsp;Meijuan Sun ,&nbsp;Zhiyuan Xun ,&nbsp;Xiaodong Yang ,&nbsp;Guijun Zhao ,&nbsp;Haiyun Li ,&nbsp;Xuejun Liu","doi":"10.1016/j.ejpsy.2023.07.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><p><span>Blonanserin is a second-generation </span>antipsychotic<span> (SGA)for the treatment of schizophrenia and has been approved for use in Japan, South Korea and China. This analysis aimed to evaluate the effectiveness and safety of blonanserin in Chinese adolescent patients, using data from a post-marketing surveillance of blonanserin started in September 2018.</span></p></div><div><h3>Methods</h3><p>A 12-week, prospective, multi-center, open-label post-marketing surveillance was conducted. Patients in this analysis were stratified by age.</p></div><div><h3>Results</h3><p>78 patients with schizophrenia aged &lt; 18 years were included. The incidence of adverse drug reactions<span> in adolescent patients was 33.3% significantly higher than patients over 40 years old. After 12-week treatment, 8.1% of adolescent patients had a weight gain ≥ 7%, and it was not significantly different from other age groups. Mean Brief Psychiatric Rating Scale (BPRS) total score was significantly reduced at week 12, and the decline of anergia score and thought disturbance score of adolescent patients was significantly greater than in adults.</span></p></div><div><h3>Conclusions</h3><p>Blonanserin was well tolerated and effective in the treatment of schizophrenia in Chinese adolescent patients in real-world clinical practice. Blonanserin might be a reasonable choice for the treatment of schizophrenia in adolescent patients.</p></div>","PeriodicalId":12045,"journal":{"name":"European Journal of Psychiatry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213616323000356","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives

Blonanserin is a second-generation antipsychotic (SGA)for the treatment of schizophrenia and has been approved for use in Japan, South Korea and China. This analysis aimed to evaluate the effectiveness and safety of blonanserin in Chinese adolescent patients, using data from a post-marketing surveillance of blonanserin started in September 2018.

Methods

A 12-week, prospective, multi-center, open-label post-marketing surveillance was conducted. Patients in this analysis were stratified by age.

Results

78 patients with schizophrenia aged < 18 years were included. The incidence of adverse drug reactions in adolescent patients was 33.3% significantly higher than patients over 40 years old. After 12-week treatment, 8.1% of adolescent patients had a weight gain ≥ 7%, and it was not significantly different from other age groups. Mean Brief Psychiatric Rating Scale (BPRS) total score was significantly reduced at week 12, and the decline of anergia score and thought disturbance score of adolescent patients was significantly greater than in adults.

Conclusions

Blonanserin was well tolerated and effective in the treatment of schizophrenia in Chinese adolescent patients in real-world clinical practice. Blonanserin might be a reasonable choice for the treatment of schizophrenia in adolescent patients.

口服布洛南色林治疗中国青少年精神分裂症的安全性和有效性:上市后12周监测数据
背景与目的博那赛林是一种治疗精神分裂症的第二代抗精神病药物,已在日本、韩国和中国被批准使用。本分析旨在利用2018年9月开始的布隆色林上市后监测数据,评估布隆色素在中国青少年患者中的有效性和安全性。方法进行为期12周的前瞻性、多中心、开放标签的上市后监测。该分析中的患者按年龄分层。结果78例精神分裂症患者年龄<;18岁。青少年患者的药物不良反应发生率显著高于40岁以上患者33.3%。经过12周的治疗,8.1%的青少年患者体重增加≥7%,与其他年龄组没有显著差异。在第12周,平均简明精神病评定量表(BPRS)总分显著降低,青少年患者的无能评分和思维障碍评分的下降幅度明显大于成年人。结论在中国青少年精神分裂症的临床实践中,克隆安西林具有良好的耐受性和有效性。Blonanserin可能是治疗青少年精神分裂症的合理选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.90
自引率
0.00%
发文量
40
审稿时长
43 days
期刊介绍: The European journal of psychiatry is a quarterly publication founded in 1986 and directed by Professor Seva until his death in 2004. It was originally intended to report “the scientific activity of European psychiatrists” and “to bring about a greater degree of communication” among them. However, “since scientific knowledge has no geographical or cultural boundaries, is open to contributions from all over the world”. These principles are maintained in the new stage of the journal, now expanded with the help of an American editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信